# Parkervision Inc: financial statements, quarterly

PRKR · OTC · CIK 914139 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prkr.md) · [Financials](/companies/prkr/financials.md) · [Filings](/companies/prkr/filings.md) · [Insiders](/companies/prkr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prkr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-034894.md) | [0.0 d](/filings/0001437749-25-008997.md) | [0.0](/filings/0001437749-25-016431.md) | [0.0](/filings/0001437749-25-026192.md) | [0.0](/filings/0001437749-25-034434.md) | [0.0 d](/filings/0001437749-26-009391.md) | [0.0](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) | [0.0](/filings/0001437749-25-034434.md) | not reported | [0.0](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) |
| Cost of revenue | $m | [0.1](/filings/0001437749-24-034894.md) | [0.1 d](/filings/0001437749-25-008997.md) | [0.1](/filings/0001437749-25-016431.md) | [0.1](/filings/0001437749-25-026192.md) | [0.1](/filings/0001437749-25-034434.md) | [0.1 d](/filings/0001437749-26-009391.md) | [0.1](/filings/0001437749-26-015572.md) | [0.1](/filings/0001437749-26-026266.md) | [0.1](/filings/0001437749-25-034434.md) | [0.0 d](/filings/0001437749-26-009391.md) | [0.0](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) |
| Gross profit | $m | [(0.1)](/filings/0001437749-24-034894.md) | [(0.1) d](/filings/0001437749-25-008997.md) | [(0.1)](/filings/0001437749-25-016431.md) | [(0.1)](/filings/0001437749-25-026192.md) | [(0.1)](/filings/0001437749-25-034434.md) | [(0.1) d](/filings/0001437749-26-009391.md) | [(0.1)](/filings/0001437749-26-015572.md) | [(0.1)](/filings/0001437749-26-026266.md) | [(0.1)](/filings/0001437749-25-034434.md) | [(0.0) d](/filings/0001437749-26-009391.md) | [(0.0)](/filings/0001437749-26-015572.md) | [(0.0)](/filings/0001437749-26-026266.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [0.9](/filings/0001437749-24-034894.md) | [0.6 d](/filings/0001437749-25-008997.md) | [0.8](/filings/0001437749-25-016431.md) | [0.7](/filings/0001437749-25-026192.md) | [1.0](/filings/0001437749-25-034434.md) | [1.8 d](/filings/0001437749-26-009391.md) | [1.2](/filings/0001437749-26-015572.md) | [3.8](/filings/0001437749-26-026266.md) | [1.5](/filings/0001437749-25-034434.md) | [1.0 d](/filings/0001437749-26-009391.md) | [1.0](/filings/0001437749-26-015572.md) | [1.5](/filings/0001437749-26-026266.md) |
| Interest expense | $m | [0.1](/filings/0001437749-23-031965.md) | [0.1 d](/filings/0001437749-24-008859.md) | [0.1](/filings/0001437749-24-016614.md) | [0.1](/filings/0001437749-25-026192.md) | [0.1](/filings/0001437749-25-034434.md) | [0.1 d](/filings/0001437749-26-009391.md) | [0.1](/filings/0001437749-26-015572.md) | [0.1](/filings/0001437749-26-026266.md) | [0.1](/filings/0001437749-25-034434.md) | [0.1 d](/filings/0001437749-26-009391.md) | [0.1](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-034894.md) | [0.0 d](/filings/0001437749-25-008997.md) | [0.0](/filings/0001437749-25-016431.md) | [0.0](/filings/0001437749-25-026192.md) | [0.0](/filings/0001437749-25-034434.md) | [0.0 d](/filings/0001437749-26-009391.md) | [0.0](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) | [0.0](/filings/0001437749-25-034434.md) | [0.0 d](/filings/0001437749-26-009391.md) | [0.0](/filings/0001437749-26-015572.md) | [0.0](/filings/0001437749-26-026266.md) |
| Net income | $m | [(3.9)](/filings/0001437749-24-034894.md) | [(1.1) d](/filings/0001437749-25-008997.md) | [(0.7)](/filings/0001437749-25-016431.md) | [(0.3)](/filings/0001437749-25-026192.md) | [(10.8)](/filings/0001437749-25-034434.md) | [(2.6) d](/filings/0001437749-26-009391.md) | [(3.8)](/filings/0001437749-26-015572.md) | [(1.6)](/filings/0001437749-26-026266.md) | [(2.0)](/filings/0001437749-25-034434.md) | [(0.0) d](/filings/0001437749-26-009391.md) | [(1.6)](/filings/0001437749-26-015572.md) | [0.1](/filings/0001437749-26-026266.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001437749-24-034894.md) | not reported | [(0.01)](/filings/0001437749-24-016614.md) | [0.00](/filings/0001437749-24-026374.md) | [(0.12)](/filings/0001437749-24-034894.md) | not reported | not reported | [(0.01)](/filings/0001437749-26-026266.md) | not reported | not reported | not reported | [0.00](/filings/0001437749-26-026266.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0001437749-24-034894.md) | not reported | [(0.01)](/filings/0001437749-25-016431.md) | [0.00](/filings/0001437749-25-026192.md) | [(0.12)](/filings/0001437749-25-034434.md) | not reported | [(0.03)](/filings/0001437749-26-015572.md) | [(0.01)](/filings/0001437749-26-026266.md) | [(0.02)](/filings/0001437749-25-034434.md) | not reported | [(0.01)](/filings/0001437749-26-015572.md) | [0.00](/filings/0001437749-26-026266.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.3](/filings/0001437749-23-031965.md) | [2.6](/filings/0001437749-25-008997.md) | [1.7](/filings/0001437749-24-016614.md) | [1.0](/filings/0001437749-24-026374.md) | [0.8](/filings/0001437749-24-034894.md) | [4.9](/filings/0001437749-26-009391.md) | [3.3](/filings/0001437749-25-016431.md) | [2.0](/filings/0001437749-25-026192.md) | [0.9](/filings/0001437749-25-034434.md) | [4.4](/filings/0001437749-26-026266.md) | [3.4](/filings/0001437749-26-015572.md) | [2.5](/filings/0001437749-26-026266.md) |
| Current assets | $m | [3.5](/filings/0001437749-23-031965.md) | [2.7](/filings/0001437749-25-008997.md) | [1.8](/filings/0001437749-24-016614.md) | [1.1](/filings/0001437749-24-026374.md) | [0.9](/filings/0001437749-24-034894.md) | [5.0](/filings/0001437749-26-009391.md) | [3.5](/filings/0001437749-25-016431.md) | [2.3](/filings/0001437749-25-026192.md) | [1.2](/filings/0001437749-25-034434.md) | [4.7](/filings/0001437749-26-026266.md) | [3.8](/filings/0001437749-26-015572.md) | [3.1](/filings/0001437749-26-026266.md) |
| Total assets | $m | [4.6](/filings/0001437749-23-031965.md) | [4.0](/filings/0001437749-25-008997.md) | [3.1](/filings/0001437749-24-016614.md) | [2.4](/filings/0001437749-24-026374.md) | [1.8](/filings/0001437749-24-034894.md) | [5.9](/filings/0001437749-26-009391.md) | [4.3](/filings/0001437749-25-016431.md) | [3.1](/filings/0001437749-25-026192.md) | [1.9](/filings/0001437749-25-034434.md) | [5.4](/filings/0001437749-26-026266.md) | [4.5](/filings/0001437749-26-015572.md) | [3.7](/filings/0001437749-26-026266.md) |
| Current liabilities | $m | [2.6](/filings/0001437749-23-031965.md) | [2.3](/filings/0001437749-25-008997.md) | [2.5](/filings/0001437749-24-016614.md) | [2.4](/filings/0001437749-24-026374.md) | [2.4](/filings/0001437749-24-034894.md) | [2.4](/filings/0001437749-26-009391.md) | [2.9](/filings/0001437749-25-016431.md) | [2.5](/filings/0001437749-25-026192.md) | [2.9](/filings/0001437749-25-034434.md) | [2.4](/filings/0001437749-26-026266.md) | [2.1](/filings/0001437749-26-015572.md) | [2.3](/filings/0001437749-26-026266.md) |
| Total liabilities | $m | [43.5](/filings/0001437749-23-031965.md) | [43.5](/filings/0001437749-25-008997.md) | [43.2](/filings/0001437749-24-016614.md) | [42.6](/filings/0001437749-24-026374.md) | [52.1](/filings/0001437749-24-034894.md) | [52.3](/filings/0001437749-26-009391.md) | [53.9](/filings/0001437749-25-016431.md) | [51.4](/filings/0001437749-25-026192.md) | [51.7](/filings/0001437749-25-034434.md) | [50.5](/filings/0001437749-26-026266.md) | [50.0](/filings/0001437749-26-015572.md) | [48.3](/filings/0001437749-26-026266.md) |
| Long-term debt | $m | not reported | [0.5](/filings/0001437749-24-008859.md) | not reported | not reported | not reported | [0.3](/filings/0001437749-25-008997.md) | not reported | not reported | not reported | [0.2](/filings/0001437749-26-009391.md) | not reported | not reported |
| Shareholders' equity | $m | [(38.9)](/filings/0001437749-24-034894.md) | [(39.5)](/filings/0001437749-26-009391.md) | [(40.0)](/filings/0001437749-25-034434.md) | [(40.2)](/filings/0001437749-25-034434.md) | [(50.3)](/filings/0001437749-25-034434.md) | [(46.4)](/filings/0001437749-26-026266.md) | [(49.6)](/filings/0001437749-26-026266.md) | [(48.3)](/filings/0001437749-26-026266.md) | [(49.8)](/filings/0001437749-25-034434.md) | [(45.1)](/filings/0001437749-26-026266.md) | [(45.5)](/filings/0001437749-26-026266.md) | [(44.6)](/filings/0001437749-26-026266.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(735) d](/filings/0001437749-24-034894.md) | [(740) d](/filings/0001437749-25-008997.md) | [(793)](/filings/0001437749-25-016431.md) | [(625) d](/filings/0001437749-25-026192.md) | [(640) d](/filings/0001437749-25-034434.md) | [(1,158) d](/filings/0001437749-26-009391.md) | [(1,827)](/filings/0001437749-26-015572.md) | [(1,142) d](/filings/0001437749-26-026266.md) | [(1,102) d](/filings/0001437749-25-034434.md) | [(1,072) d](/filings/0001437749-26-009391.md) | [(851)](/filings/0001437749-26-015572.md) | [(886) d](/filings/0001437749-26-026266.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-24-034894.md) | [1.0 d](/filings/0001437749-25-008997.md) | [0.0](/filings/0001437749-24-016614.md) | [0.0 d](/filings/0001437749-24-026374.md) | [0.0 d](/filings/0001437749-25-034434.md) | [0.0 d](/filings/0001437749-26-009391.md) | not reported | not reported | not reported | [(1.0) d](/filings/0001437749-26-009391.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q2 FY2025 (2025-06-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [71.9](/filings/0000914139-22-000018.md) | [106](/filings/0001437749-23-014563.md) | [78.0](/filings/0001437749-23-023662.md) | [78.5](/filings/0001437749-23-031965.md) | [122](/filings/0001437749-24-016614.md) | [120](/filings/0001437749-24-026374.md) | [86.3](/filings/0001437749-24-034894.md) | [88.2](/filings/0001437749-24-016614.md) | [88.7](/filings/0001437749-24-026374.md) | [90.3](/filings/0001437749-24-034894.md) | [119](/filings/0001437749-26-026266.md) | [169](/filings/0001437749-26-026266.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 148,226,874 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026266.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.